Technology | August 29, 2006

Catheter Doubles Clot-Removing Power, Offered in RE Platform


The Spiroflex VG Catheter provides over twice the clot removing power compared to the 4F XMI and Spiroflex catheters. It is also the first AngioJet catheter of its size to be offered in a Rapid Exchange platform.
Utilizing its proprietary Spiroflex shaft technology, the catheter benefits from several design improvements made to the most recent generation of Possis Medical products. The catheter offers improved trackability inside the vessel and includes tip and hub improvements found on the recently introduced Spiroflex catheter.
The Spiroflex VG Catheter is now fully released for sale in the U.S. for peripheral use and Possis will submit for coronary approval in the U.S. in the near future. International CE Mark approval for coronary and peripheral use is pending.


Additional Content

News | Catheters

Nov. 4, 2026 — Evident Vascular has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Evident ...

Home November 05, 2026
Home
News | Catheters

Sept. 14, 2026 — Interventional Medical Device Solutions (IMDS), has announced the U.S. launch of NHanceIT, an over-the ...

Home September 15, 2026
Home
News | Catheters

June 30, 2026 — Penumbra Inc. has received the CE Mark for Red 72 Silver Label and Red 72 Silver Label with SENDit ...

Home July 02, 2026
Home
News | Catheters

Feb. 12, 2026 – CellProthera has acquired the transendocardial catheter originally developed by Celyad Oncology. This ...

Home February 12, 2026
Home
News | Catheters

Oct. 23, 2025— Emboline, Inc., a provider of full-body embolic protection devices for transcatheter procedures, thas ...

Home October 28, 2025
Home
Subscribe Now